鼻渊舒口服液联合羟甲唑啉治疗慢性鼻-鼻窦炎的临床研究  

Clinical study on of Biyuanshu Oral Liquid combined with oxymetazoline in treatment of chronic rhinosinusitis

作　　者：龚辉成[1] 谢佳[1] 颜永毅[1] 陈菲菲[1] GONG Huicheng;XIE Jia;YAN Yongyi;CHEN Feifei(Guangzhou Twelfth People’s Hospital,Guangzhou 510620,China)

机构地区：[1]广州市第十二人民医院,广东广州510620

出　　处：《现代药物与临床》2024年第11期2866-2870,共5页Drugs & Clinic

基　　金：广东省医学科研基金项目(B2024258);广州市科技计划项目(2024A03J0492)。

摘　　要：目的探讨鼻渊舒口服液联合盐酸羟甲唑啉治疗慢性鼻-鼻窦炎的临床疗效。方法选取2022年3月—2024年4月广州市第十二人民医院收治的鼻炎患者106例,依据用药情况分为对照组(53例)和治疗组(53例)。对照组给予盐酸羟甲唑啉喷雾剂,一侧1~3喷/次,2次/d。治疗组在对照组的基础上口服鼻渊舒口服液,10 mL/次,2次/d。两组患者均用药7周。观察两组患者临床疗效,比较治疗前后两组患者症状好转时间,鼻腔鼻窦结局测试量表评分(SNOT-20),及血清缺氧诱导因子-1α(HIF-1α)、白细胞介素-1β(IL-β)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平。结果治疗后,治疗组总有效率为96.23%,明显高于对照组(83.02%,P<0.05)。治疗后,与对照组比较,治疗组症状好转时间均明显短于对照组(P<0.05)。治疗后,治疗组SNOT-20评分明显低于治疗前(P<0.05),且明显低于对照组(P<0.05)。治疗后,两组患者血清IL-1β、IL-6、TNF-α、HIF-1α水平明显低于治疗前(P<0.05),且治疗后治疗组患者血清炎性因子水平明显低对照组(P<0.05)。结论鼻渊舒口服液联合盐酸羟甲唑啉治疗慢性鼻-鼻窦炎,能改善鼻窦炎患者症状,纠正机体炎症反应状态,提高患者生活质量。Objective To explore the clinical efficacy of Biyuanshu Oral Liquid combined with oxymetazoline in treatment of chronic rhinosinusitis.Method Patients(106 cases)with chronic rhinosinusitis in Guangzhou Twelfth People's Hospital from March 2022 to April 2024 were divided into control(53 cases)and treatment(53 cases)group by situation of medication.Patients in the control group were administered with Oxymetazoline Hydrochloride Spray,1—3 sprays/time of one side nose,twice daily.Patients in the treatment group were po administered with Biyuanshu Oral Liquid,10 mL/time,twice daily.Patients in two groups were treated for 7 weeks.After treatment,the clinical evaluations were evaluated,the symptom relief time,SNOT-20 scores,and the levels of IL-1β,HIF-1α,TNF-α,and IL-6 in two groups before and after treatment were compared.Results After treatment,the total clinical effective rate in the treatment group was 96.23%,which was higher than that in the control group(83.02%,P<0.05).After treatment,compared with the control group,the time of symptoms improved in the treatment group was significantly earlier than that in the control group(P<0.05).After treatment,the SNOT-20 score in the treatment group was significantly lower than that before treatment(P<0.05),and it significantly lower than that in control group after treatment(P<0.05).After treatment,the levels of serum inflammatory factors IL-1β,IL-6,TNF-α,and HIF-1αin two groups were significantly lower than those before treatment(P<0.05),and the levels of serum inflammatory factors in the treatment group were significantly lower than those in the control group(P<0.05).Conclusion Biyuanshu Oral Liquid combined with oxymetazoline in treatment of chronic rhinosinusitis can greatly improve the symptoms of patients with sinusitis,correct the inflammatory response,and improve the quality of life of patients.

关 键 词：鼻渊舒口服液 盐酸羟甲唑啉喷雾剂 慢性鼻-鼻窦炎 鼻腔鼻窦结局测试量表评分 缺氧诱导因子-1Α 

分 类 号：R976[医药卫生—药品]